GSK announces ‘open innovation’ strategy aimed at poorest countries

Andrew Witty, Chief Executive of GlaxoSmithKline, announced a series of new initiatives to help deliver new and better medicines for people living in the world's poorest countries

• ‘Open Lab’ established with $8m seed funding for new research
• 13,500 malaria compounds to be made freely available
• New collaborations to share intellectual property for neglected tropical diseases
• Pledge to create sustainable pricing model for world's most advanced malaria candidate vaccine
• GSK African Malaria Partnership awards four new grants worth $2.5m

Link here